Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Otsuka Pharmaceutical and PDL BioPharma have announced the closing of transaction under which Otsuka has acquired PDL's rights to IV Busulfex, including trademarks, patents, intellectual property and related assets, for $200 million plus inventory value.
Subscribe to our email newsletter
This IV Busulfex is an oncology product marketed and sold in the US and Canada, and through distributors in a number of other countries.
Otsuka will oversee the outsourced manufacturing of the product, while its US affiliate, Otsuka Pharmaceutical Development & Commercialization, will investigate clinical studies for potential new indications for IV Busulfex. Another Otsuka affiliate, Otsuka America Pharmaceutical, will market the product for its current indication in the US.